Abstract
The DNA microarray technology enables the identification of the large number of genes involved in the complex deregulation of cell homeostasis taking place in cancer. Using Affymetrix microarrays, we have compared the gene expression profiles of highly purified malignant plasma cells from nine patients with multiple myeloma (MM) and eight myeloma cell lines to those of highly purified nonmalignant plasma cells (eight samples) obtained by in vitro differentiation of peripheral blood B cells. Two unsupervised clustering algorithms classified these 25 samples into two distinct clusters: a malignant plasma cell cluster and a normal plasma cell cluster. Two hundred and fifty genes were significantly up-regulated and 159 down-regulated in malignant plasma samples compared to normal plasma samples. For some of these genes, an overexpression or downregulation of the encoded protein was confirmed (cyclin D1, c-myc, BMI-1, cystatin c, SPARC, RB). Two genes overexpressed in myeloma cells (ABL and cystathionine beta synthase) code for enzymes that could be a therapeutic target with specific drugs. These data provide a new insight into the understanding of myeloma disease and prefigure that the development of DNA microarray could help to develop an ‘à la carte’ treatment in cancer disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM . et al. 2000 Nature 403: 503–511
Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R . 2001 Blood 98: 3082–3086
Bergsagel PL, Kuehl WM . 2001 Oncogene 20: 5611–5622
Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E, Garrido C . 2000 Nat. Cell. Biol. 2: 645–652
Choi SJ, Reddy SV, Devlin RD, Menaa C, Chung H, Boyce BF, Roodman GD . 1999 J. Biol. Chem. 274: 27747–27753
Clark EA, Golub TR, Lander ES, Hynes RO . 2000 Nature 406: 532–535
Coqueret O, Berube G, Nepveu A . 1998 EMBO J. 17: 4680–4694
Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS . 2000 Cancer Res. 60: 7099–7105
Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B . 1998 Br. J. Haematol. 103: 1152–1160
De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B . 2001 Blood 98: 771–780
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . 2000 Br. J. Haematol. 109: 823–828
Dysvik B, Jonassen I . 2001 Bioinformatics 17: 369–370
Eisen MB, Spellman PT, Brown PO, Botstein D . 1998 Proc. Natl. Acad. Sci. USA 95: 14863–14868
Hallek M, Leif BP, Anderson KC . 1998 Blood 91: 3–21
Hilbert DM, Migone TS, Kopf M, Leonard WJ, Rudikoff S . 1996 5: 81–89
Hirst M, Haliday E, Nakamura J, Lou L . 1994 J. Biol. Chem. 269: 23830–23837
Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H . 2000 Cancer Res. 60: 6868–6874
Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, Harousseau JL, Bataille R, Pellat-Deceunynck C . 1999 Blood 94: 701–712
Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R . 1995 Br. J. Haematol. 91: 664–667
Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R . 1984 Eur. J. Cancer Clin. Oncol. 20: 227–231
Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B . 1991 Blood 78: 1198–1204
Klein B, Zhang XG, Lu ZY, Bataille R . 1995 Blood 85: 863–872
Largaespada DA, Kaehler DA, Mishak H, Weissinger E, Potter M, Mushinski JF, Risser R . 1992 Oncogene 7: 811–819
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL . 1997 Nat. Med. 3: 171–176
Michael WM, Newport J . 1998 Science 282: 1886–1889
Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R . 1991 Cell 67: 1075–1087
Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP . 1997 Blood 89: 2500–2506
Oritani K, Kincade PW . 1996 J. Cell. Biol. 134: 771–782
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV . 2000 J. Biol. Chem. 275: 21797–21800
Pellat-Deceunynck C, Mellerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, Jotereau F, Bataille R . 2000 Eur. J. Immunol. 30: 803–809
Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K . 1992 Blood 79: 495–502
Potter M, Wiener F . 1992 Carcinogenesis 13: 1681–1697
Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RS . 1998 Blood 92: 1743–1748
Raynaud SD, Bekri S, Leroux D, Grosgeorge J, Klein B, Bastard C, Gaudray P, Simon MP . 1993 Genes. Chromosom. Cancer 8: 80–87
Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I . 1994 Mol. Cell. Biol. 14: 1431–1437
Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM . 2000 Proc. Natl. Acad. Sci. USA 97: 228–233
Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB . 2002 Proc. Natl. Acad. Sci. USA 99: 4465–4470
Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Yamamoto N, Yamamoto M . 2001 Biochim. Biophys. Acta. 1536: 1–12
Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Rème T, Legouffe E, Rossi JF, Shaughnessy Jr J, Ørntoft O, Klein B . 2002 Blood 100: 1113–1122
Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH . 2000 Cancer Res. 60: 6421–6426
Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y . 1999 Blood 94: 1393–1400
Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y . 1996 Blood 87: 3395–3403
Thykjaer T, Workman C, Kruhoffer M, Demtroder K, Wolf H, Andersen LD, Frederiksen CM, Knudsen S, Orntoft TF . 2001 Cancer Res. 61: 2492–2499
van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD . 2000 Cancer Res. 60: 5832–5838
van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A . 1991 Cell 65: 737–752
Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF . 1998 Science 281: 998–1001
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy Jr J . 2002 Blood 99: 1745–1757
Acknowledgements
We thank Eric Legouffe for providing the myeloma samples and Linda Northrup for manuscript correction. This work was supported by grants from the Ligue Nationale Contre le Cancer, Paris, France.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Vos, J., Thykjær, T., Tarte, K. et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21, 6848–6857 (2002). https://doi.org/10.1038/sj.onc.1205868
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205868
Keywords
This article is cited by
-
Targeting BMI-1 in B cells restores effective humoral immune responses and controls chronic viral infection
Nature Immunology (2022)
-
Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features
Stem Cell Research & Therapy (2020)
-
Identification of potential crucial genes and construction of microRNA-mRNA negative regulatory networks in osteosarcoma
Hereditas (2018)
-
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
British Journal of Cancer (2018)
-
Tyrosine kinase c-Abl regulates the survival of plasma cells
Scientific Reports (2017)